AG
MRNS

Advisor Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Advisor Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Hold
38
– – ﹤0.01% 5484
2019
Q3 		$0 Buy
38
+25
+192% +$202 ﹤0.01% 5467
2019
Q2 		$0 Buy
+13
New +$226 ﹤0.01% 5396

Other funds holding MRNS

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Advisor Group's MRNS Position: Q4 2019 in Review

Advisor Group held its Marinus Pharmaceuticals, Inc (MRNS) position steady in Q4 2019 at 38 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5484.

Advisor Group first reported a position in MRNS in Q2 2019 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold MRNS as of Q4 2019.

  • Advisor Group held 38 shares of Marinus Pharmaceuticals, Inc worth $0 as of Q4 2019.
  • Advisor Group left its Marinus Pharmaceuticals, Inc share count unchanged in Q4 2019.
  • Marinus Pharmaceuticals, Inc made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5484 holding.
  • Advisor Group first reported a position in Marinus Pharmaceuticals, Inc in Q2 2019 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.